FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a pharmaceutical synergetic combination for the treatment of cancer containing therapeutically effective amount of PM01183 or its pharmaceutically acceptable salt and therapeutically effective amount of a mitosis inhibitor, where the mitosis inhibitor is selected from paclitaxel, docetaxel, vincristine and vinorelbine, while the cancer to be treated is selected from lung cancer, sarcoma, prostate cancer, stomach cancer, ovarian cancer, hepatoma, breast cancer, colorectal cancer, kidney cancer and brain cancer.
EFFECT: increase in or potentiation of therapeutic efficiency of anticancer drugs.
15 cl, 296 dwg, 26 tbl, 21 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2675270C2 |
METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2014 |
|
RU2823603C2 |
Authors
Dates
2021-10-14—Published
2018-01-19—Filed